Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment

Blood (2021) 138 (Supplement 1): 4310.

https://doi.org/10.1182/blood-2021-153346

Published: 2021

Journal Articles

Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients with WHIM Syndrome: Results from the Long-Term Extension of the Open-Label Phase 2 Study

David C. Dale, Frank Caleb Firkin, Audrey Anna Bolyard, Weihua Tang, Honghua Jiang, Richard MacLeod, Diego Cadavid, Yanping Hu

Blood (2021) 138 (Supplement 1): 1121.

https://doi.org/10.1182/blood-2021-145759

Published: 2021

Journal Articles

Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations

Steven P. Treon, Christian Buske, Sheeba K Thomas, Jorge J. Castillo, Andrew R. Branagan, Meletios A. Dimopoulos, Maria Gavriatopoulou, Diego Cadavid, Felix T Garzon, Weihua Tang, Sean Seyffert, Varun Garg, Shariq Ali, Arthur G. Taveras, Kelly Chen, Jeffrey V. Matous

Blood (2021) 138 (Supplement 1): 1362.

https://doi.org/10.1182/blood-2021-144706

Published: 2021

Journal Articles

Oral Administration of Mavorixafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States

David C. Dale, Steven P. Treon, David F. McDermott, Diego Cadavid, Xia Luo, Varun Garg, Weihua Tang, Honghua Jiang, Kelly Chen, Arthur G. Taveras, Ashish Bhandari, Jean Donadieu

Blood (2021) 138 (Supplement 1): 2186.

https://doi.org/10.1182/blood-2021-152990

Published: 2021

Journal Articles

Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome

David C. Dale, Frank Firkin, Audrey Anna Bolyard, Merideth Kelley, Vahagn Makaryan, Kenneth J. Gorelick, Tarek Ebrahim, Varun Garg, Weihua Tang, Honghua Jiang, Renato Skerlj, Sarah Beaussant Cohen

Blood (2020) 136 (26): 2994–3003.

https://doi.org/10.1182/blood.2020007197

Published: 2020

Includes: Supplemental data

NARROW

Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment

Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients with WHIM Syndrome: Results from the Long-Term Extension of the Open-Label Phase 2 Study

Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations

Oral Administration of Mavorixafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States

Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome

Email alerts

ASH Publications

American Society of Hematology

Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment

Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients with WHIM Syndrome: Results from the Long-Term Extension of the Open-Label Phase 2 Study

Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations

Oral Administration of Mavorixafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States

Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only